{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:45:36Z","timestamp":1790127936558,"version":"4.0.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.mehy.2020.110053","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T19:20:58Z","timestamp":1593285658000},"page":"110053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Rethinking interleukin-6 blockade for treatment of COVID-19"],"prefix":"10.1016","volume":"144","author":[{"given":"S.","family":"Scherger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Henao-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Franco-Paredes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2020.110053_b0005","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/intimm\/dxq030","article-title":"IL-6: from its discovery to clinical applications","volume":"22","author":"Kishimoto","year":"2010","journal-title":"Int Immunol"},{"key":"10.1016\/j.mehy.2020.110053_b0010","first-page":"878","article-title":"The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochimica et Biophysica Acta (BBA) - Molecular","volume":"1813","author":"Scheller","year":"2011","journal-title":"Cell Res"},{"key":"10.1016\/j.mehy.2020.110053_b0015","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/0092-8674(89)90438-8","article-title":"Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130","volume":"58","author":"Taga","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.mehy.2020.110053_b0020","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.smim.2014.01.009","article-title":"A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy","volume":"26","author":"Tanaka","year":"2014","journal-title":"Semin Immunol"},{"key":"10.1016\/j.mehy.2020.110053_b0025","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab treatment in COVID-19: a single center experience","author":"Luo","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.mehy.2020.110053_b0030","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.4049\/jimmunol.143.11.3517","article-title":"IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice","volume":"143","author":"Aderka","year":"1989","journal-title":"J Immunol"},{"key":"10.1016\/j.mehy.2020.110053_b0035","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1172\/JCI1368","article-title":"IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses","volume":"101","author":"Xing","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.mehy.2020.110053_b0040","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12931-017-0553-6","article-title":"Interleukin-6 displays lung anti-inflammatory properties and exerts protective hemodynamic effects in a double-hit murine acute lung injury","volume":"18","author":"Voiriot","year":"2017","journal-title":"Respir Res"},{"key":"10.1016\/j.mehy.2020.110053_b0045","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/blood.V83.1.113.113","article-title":"Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55","volume":"83","author":"Tilg","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.mehy.2020.110053_b0050","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1182\/blood.V84.5.1434.1434","article-title":"Effects of recombinant human interleukin-6 in cancer patients: a phase 1\u201311 study","volume":"84","author":"van Gameren","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.mehy.2020.110053_b0055","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/368339a0","article-title":"Impaired immune and acute-phase responses in interleukin-6-deficient mice","volume":"368","author":"Kopf","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.mehy.2020.110053_b0060","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1086\/514062","article-title":"Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia","volume":"176","author":"van der Poll","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.mehy.2020.110053_b0065","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/mi.2012.2","article-title":"Essential role of IL-6 in protection against H1N1 influenza virus by promoting neutrophil survival in the lung","volume":"5","author":"Dienz","year":"2012","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.mehy.2020.110053_b0070","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/eji.201243018","article-title":"Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology: Immunity to infection","volume":"43","author":"Lauder","year":"2013","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.mehy.2020.110053_b0075","doi-asserted-by":"crossref","first-page":"43829","DOI":"10.1038\/srep43829","article-title":"IL-6 ameliorates acute lung injury in influenza virus infection","volume":"7","author":"Yang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.mehy.2020.110053_b0080","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.3389\/fimmu.2019.03102","article-title":"IL-6 during influenza-streptococcus pneumoniae co-infected pneumonia\u2014a protector","volume":"10","author":"Gou","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.mehy.2020.110053_b0085","doi-asserted-by":"crossref","unstructured":"Cox MJ, Loman N, Bogaert D, O\u2019Grady J. Co-infections: potentially lethal and unexplored in COVID-19. The Lancet Microbe 2020:S2666524720300094. doi: 10.1016\/S2666-5247(20)30009-4.","DOI":"10.1016\/S2666-5247(20)30009-4"},{"key":"10.1016\/j.mehy.2020.110053_b0090","doi-asserted-by":"crossref","DOI":"10.1111\/tri.13611","article-title":"Why the immune system fails to mount an adaptive immune response to a Covid -19 infection","author":"Ahmadpoor","year":"2020","journal-title":"Transpl Int"},{"key":"10.1016\/j.mehy.2020.110053_b0095","article-title":"Potential therapeutic agents against COVID-19: What we know so far","volume":"1","author":"Lu","year":"2020","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.mehy.2020.110053_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality","author":"Zhang","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.mehy.2020.110053_b0105","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1479-5876-9-113","article-title":"Serum cytokine profiles in healthy young and elderly population assessed using multiplexed bead-based immunoassays","volume":"9","author":"Kim","year":"2011","journal-title":"J Transl Med"},{"key":"10.1016\/j.mehy.2020.110053_b0110","first-page":"12","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"26","author":"Xu","year":"2020","journal-title":"ChinaXiV"},{"key":"10.1016\/j.mehy.2020.110053_b0115","article-title":"Pneumonia in Wuhan, China","volume":"2020","author":"Wu","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.mehy.2020.110053_b0120","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.mehy.2020.110053_b0125","article-title":"Interleukin-6 in COVID-19: a systematic review and meta-analysis","author":"Coomes","year":"2020","journal-title":"Intensive Care and Critical Care Medicine"},{"key":"10.1016\/j.mehy.2020.110053_b0130","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.3899\/jrheum.121389","article-title":"Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis","volume":"40","author":"Shimamoto","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.mehy.2020.110053_b0135","doi-asserted-by":"crossref","unstructured":"Diaz-Torne C, Ortiz M dels A, Moya P, Hernandez MV, Reina D, Castellvi I, et al. The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab. Seminars in Arthritis and Rheumatism 2018;47:757\u201364. doi: 10.1016\/j.semarthrit.2017.10.022.","DOI":"10.1016\/j.semarthrit.2017.10.022"},{"key":"10.1016\/j.mehy.2020.110053_b0140","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.semarthrit.2015.02.002","article-title":"Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab","volume":"45","author":"Berti","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.mehy.2020.110053_b0145","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4103\/0022-3859.188550","article-title":"Do high sensitivity C-reactive protein and serum interleukin-6 levels correlate with disease activity in systemic lupus erythematosus patients?","volume":"63","author":"Umare","year":"2017","journal-title":"J Postgrad Med"},{"key":"10.1016\/j.mehy.2020.110053_b0150","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1210\/jcem.82.12.4422","article-title":"Dose-dependent effects of recombinant human interleukin-6 on glucose regulation","volume":"82","author":"Tsigos","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.mehy.2020.110053_b0155","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1084\/jem.20190344","article-title":"Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses","volume":"216","author":"Spencer","year":"2019","journal-title":"J Exp Med"},{"key":"10.1016\/j.mehy.2020.110053_b0160","doi-asserted-by":"crossref","first-page":"647","DOI":"10.4049\/jimmunol.180.1.647","article-title":"Recurrent Staphylococcal Cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6","volume":"180","author":"Puel","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.mehy.2020.110053_b0165","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab clinical trials","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.mehy.2020.110053_b0170","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40744-019-0150-x","article-title":"Tocilizumab patterns of use, effectiveness, and safety in patients with rheumatoid arthritis: final results from a set of multi-national non-interventional studies","volume":"6","author":"Haraoui","year":"2019","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.mehy.2020.110053_b0175","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","article-title":"Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)","volume":"77","author":"Khanna","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.mehy.2020.110053_b0180","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrrheum.2017.83","article-title":"The role of IL-6 in host defence against infections: immunobiology and clinical implications","volume":"13","author":"Rose-John","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.mehy.2020.110053_b0185","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/14397595.2015.1074648","article-title":"Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: results from a randomized phase II trial","volume":"26","author":"Takeuchi","year":"2016","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.mehy.2020.110053_b0190","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1136\/annrheumdis-2013-204760","article-title":"Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study","volume":"73","author":"Genovese","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.mehy.2020.110053_b0195","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1177\/0091270009350623","article-title":"Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis","volume":"50","author":"Frey","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.mehy.2020.110053_b0200","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s40262-015-0296-9","article-title":"Clinical pharmacokinetics and pharmacodynamics of monoclonal antibodies approved to treat rheumatoid arthritis","volume":"54","author":"Ternant","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.mehy.2020.110053_b0205","article-title":"IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections","author":"Kimmig","year":"2020","journal-title":"Intensive Care and Critical Care Medicine"},{"key":"10.1016\/j.mehy.2020.110053_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID- 19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.mehy.2020.110053_b0215","doi-asserted-by":"crossref","unstructured":"Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. The Lancet 2020:S0140673620311806. doi: 10.1016\/S0140-6736(20)31180-6.","DOI":"10.1016\/S0140-6736(20)31180-6"},{"key":"10.1016\/j.mehy.2020.110053_b0220","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.8630","article-title":"Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State","author":"Rosenberg","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.mehy.2020.110053_b0225","unstructured":"Seto T. A Randomized, Controlled Clinical Trial of the Safety and Efficacy of Tocilizumab for the Treatment of Severe COVID-19. clinicaltrials.gov; 2020."},{"key":"10.1016\/j.mehy.2020.110053_b0230","unstructured":"Genentech, Inc. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia. clinicaltrials.gov; 2020."}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720310653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720310653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:28:10Z","timestamp":1759692490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987720310653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":46,"alternative-id":["S0306987720310653"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2020.110053","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rethinking interleukin-6 blockade for treatment of COVID-19","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2020.110053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110053"}}